Real-World Safety and Effectiveness of Cladribine Tablets in Older (≥ 50 Years) Patients with Relapsing Multiple Sclerosis: Results from the "Aging" Study-A Multicenter, Single-Arm, Phase 4 Observational Study.
INTRODUCTION Older patients with relapsing multiple sclerosis (PwRMS) are often underrepresented in clinical trials, limiting evidence on the safety and effectiveness of disease-modifying therapies. This study characterized the safety and effectiveness of short-course treatment with cladribine tablets (CladT) over 24 m...